Loading
Pay more for drugs that clearly help people live longer or better, and less for those that barely move the needle, using a public benefit scale doctors already use.
National payers adopt a rule that reimbursed price at launch is tied to the ESMO Magnitude of Clinical Benefit Scale (or ASCO Value Framework) grade of the pivotal evidence, with a mandatory renegotiation when overall survival or quality-of-life data mature. Grade 4 to 5 (or A to B in curative settings) commands a premium band; grade 1 to 2 is reimbursed only at or near the price of the comparator. Several European payers already consult the scale informally; making the link explicit and automatic changes the return calculus for marginal drugs before they enter development.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Progression-free survival (PFS), Overall survival (OS).
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Progression-free survival (PFS), Overall survival (OS), Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Progression-free survival (PFS), Overall survival (OS).
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.